A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

Recruiting

AbrocitinibA Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

Sponsor:

Pfizer

Code:

NCT05721937

Conditions

Atopic Dermatitis

Eligibility Criteria

Sex: Female

Age: 0 - 70+

Healthy Volunteers: Accepted

Interventions

Abrocitinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Pfizer on 2025-05-13.